A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 02 Sep 2014
At a glance
- Drugs Siltuximab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Biotech
- 07 Jun 2017 Biomarkers information updated
- 30 Jun 2014 Protocol has been amended with a change in primary outcome measures.
- 19 Oct 2007 Status changed from in progress to completed.